Search
terms-of-sale-07-2022-eng-pv-incl-accessible (1)
EQVALAN® GOLD
EQVALAN® GOLD
CONTINUUM
CONTINUUM, a collaborative project, investigates how digital technology can help healthcare professionals manage complex patient cases at home. Keep reading.
Vaccine protection against different PRRS virus strains
Vaccine protection against different PRRS virus strains
Research Manitoba and Boehringer Ingelheim Canada Partnership to Invest in Diabetes Care in Indigenous Populations in Manitoba
Research Manitoba and Boehringer Ingelheim Canada Partnership to Invest in Diabetes Care in Indigenous Populations in Manitoba
Introducing Ingelvac Provenza™ — Stop influenza A Virus in swine where it starts
Introducing Ingelvac Provenza™ — Stop influenza A Virus in swine where it starts
Boehringer Ingelheim’s latest investigational treatment slowed lung function decline in people living with idiopathic pulmonary fibrosis
Promising 12-week Phase II trial data with BI 1015550, a novel investigational phosphodiesterase 4B (PDE4B) inhibitor, published in The New England Journal of Medicine Potential new treatment for progressive pulmonary fibrosis (PPF) builds on Boehringer
Good business performance gives Boehringer Ingelheim tailwind for investment in R&D
R&D investment up 11.7% to 4.1 billion EUR in 2021 (20.0% of net sales) More than 25 billion EUR investment in R&D and 7 billion EUR in capital expenditure over the next five years Human Pharma pipeline acceleration: up to 15 new product launches
Boehringer Ingelheim Canada’s national program is helping people living with diabetes and heart failure by addressing health system gaps
Boehringer Ingelheim Canada’s national program is helping people living with diabetes and heart failure by addressing health system gaps
Boehringer Ingelheim reaches more patients than ever in 2022 as innovative medicines drive growth
• Medicines reached a record 30 million people, driven by JARDIANCE® and OFEV® • R&D investments of 5 billion EUR, or 21 percent of net sales • Net sales rise 10.5 percent (currency adjusted), up strongly to 24.1 billion EUR
Boehringer Ingelheim increases commitments to sustainable development
Boehringer Ingelheim increases commitments to sustainable development
Saskatchewan Health Research Foundation and Boehringer Ingelheim Canada Partner to Improve Chronic Diseases Care in Saskatchewan’s Indigenous Communities
Saskatchewan Health Research Foundation and Boehringer Ingelheim Canada Partner to Improve Chronic Diseases Care in Saskatchewan’s Indigenous Communities
Breathing new life into patient care: Innovative partnership aims to transform interstitial lung disease support
Burlington, ON (October 25, 2023) – In a unique partnership, Boehringer Ingelheim (Canada) Ltd., St. Joseph's Healthcare Hamilton, and McMaster University have come together to transform the way patients are supported at the onset of a diagnosis
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
Equine asthma: Recognizing and managing respiratory issues in horses
Equine asthma: Recognizing and managing respiratory issues in horses
Boehringer Ingelheim and WHO Foundation join forces to promote equitable access to healthcare and increase efforts for suicide prevention
Boehringer Ingelheim and WHO Foundation join forces to promote equitable access to healthcare and increase efforts for suicide prevention
Our code of conduct
BI-Company-Profile-2022
supplier-code-of-conduct-english
supplier_code_of_conduct_brochure_-_en_2020.pdf
ofevpmfr
ofevcifr
Daniel Kiesenhofer
Daniel Kiesenhofer talks about his role as Project Manager Quality Control at Boehringer Ingelheim in Vienna, Austria.
Prof. Eric Haaksma
Prof. Eric Haaksma speaks about his career and Boehringer Ingelheim's mission to transform lives for generations.